The abstract is read at the publisher; the summary is JClub's.
Global economic evaluation of COVID-19 vaccination from 8 December 2020 to 8 December 2021 estimates return-on-investment of $59.7–$809 per dollar invested in the base case.
- Why it matters: The work addresses how to quantify economic benefits versus the costs of rapid vaccine development, manufacturing, and delivery during the first year of rollout.
- What they did: It estimates life years and QALYs gained from averted deaths, infections, and hospitalizations, values benefits via cost-benefit and cost-effectiveness approaches, and compares them with $79.4 billion in development and delivery costs.
- The result: Probabilistic sensitivity analysis yields ROIs of $60.3–$753, with high-income countries showing the greatest health benefits per person vaccinated and low-income countries the greatest nonhealth benefits per person.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.